# BPC-157 Dosage Research Context — Animal Study Parameters > Research-context summary of BPC-157 dosing parameters from animal studies: dose ranges by route, pharmacokinetic parameters, half-life, bioavailability, and the state of human pilot data. For research purposes only. ## Research Dose Ranges by Route The following dose parameters are drawn from the published preclinical and pilot research literature. They represent what was administered to animals in experimental settings. They do not constitute recommendations for human use. **Intraperitoneal (IP) — most common preclinical route.** The dose most frequently cited across the rodent literature is 10 µg/kg/day [1][4][6][14]. A lower-dose bracket of 10 ng/kg/day was tested in the same-study comparisons and consistently produced results similar to the 10 µg/kg arm [1][4][6][14]. An extreme low-dose test — 10 pg/kg — was administered in the Achilles tendon-to-bone healing study and still demonstrated measurable functional improvement [1]. **Oral / drinking water.** BPC-157 was administered via drinking water in multiple GI and musculoskeletal studies, typically at the same 10 µg/kg and 10 ng/kg dose brackets [6][7][14]. Its unusual gastric stability made oral delivery experimentally viable [8][17]. **Intramuscular (IM).** The gastric ulcer protection studies used IM delivery at 400–800 ng/kg, a notably lower effective dose bracket than the IP range used in musculoskeletal models [5]. This suggests route-dependent pharmacokinetics. **Intragastric.** Used in the same gastric ulcer models at 400–800 ng/kg [5]. **Intravenous (IV).** Used in the 2022 pharmacokinetic characterization study in rats and dogs [13]. The highest dose tested in a human pilot was 20 mg IV, administered as a single infusion [15]. **Spinal cord injury acute model.** A single intraperitoneal dose of 200 µg/kg or 2 µg/kg administered 10 minutes after compression injury in rats produced sustained functional recovery through 360 days [10]. **In vitro (fibroblast culture).** BPC-157 was applied to rat Achilles tendon fibroblasts at 0.1, 0.25, and 0.5 µg/mL concentrations. The 7-fold increase in GHR mRNA and protein was observed at 0.5 µg/mL by day 3 [2]. In vitro concentrations are not directly translatable to in vivo dose requirements. ## Pharmacokinetics: Half-Life, Bioavailability, and Distribution The pharmacokinetic profile of BPC-157 was characterized in a 2022 Frontiers in Pharmacology study using rats and beagle dogs [13]. **Elimination half-life.** Following IV administration, the elimination half-life (t½) was under 30 minutes in both rats and dogs [13]. **Intramuscular bioavailability.** IM bioavailability was 14.49–19.35% in rats and 45.27–50.56% in beagle dogs [13]. The approximately 3-fold difference between species is notable and raises questions about bioavailability in humans that remain uncharacterized. **Distribution.** Following IV dosing, the highest concentrations were found in the kidney and liver within 3 minutes of administration [13]. **Metabolism and excretion.** BPC-157 is metabolized rapidly to its constituent amino acids [13]. Elimination occurred primarily via urine and bile. No active metabolites have been described. **Pharmacokinetic linearity.** Pharmacokinetics were linear across the dose range studied [13]. **Stability context.** The peptide's four proline residues confer resistance to proteolytic cleavage in gastric or intestinal environments [8][17]. This gastric stability is mechanistically distinct from systemic pharmacokinetics — the peptide is stable in GI fluids but cleared rapidly from systemic circulation once absorbed. **No human pharmacokinetic data exist.** The ADME profile of BPC-157 in humans is uncharacterized [17]. ## Routes Studied The following routes appear in the published literature: intraperitoneal [1][4][6][10][14], oral gavage / drinking water [5][6][7][14], intramuscular [5][13], intravenous [13][15], subcutaneous [15], local / topical at wound site [7], intragastric [5], rectal enema (Phase II PL 14736 UC trial) [8], intra-articular (human pilot) [15], intravesicular (human pilot) [15]. The effective dose in the gastric ulcer IM model (400–800 ng/kg) is several orders of magnitude lower than the IP dose used in most musculoskeletal models (10 µg/kg) [5][1]. **Human pilot summary.** The three published human pilots administered BPC-157 via intra-articular injection, intravesicular instillation, and intravenous infusion (up to 20 mg) [15]. No major adverse events were reported. Sample sizes were very small (n=2 to n=16). These pilots are exploratory safety observations, not efficacy data sufficient for clinical conclusions. ## Regulatory and Purity Context The FDA's Category 2 designation (September 2023) reflects a determination that BPC-157 lacks sufficient human safety data to permit compounding in licensed US pharmacies under Sections 503A and 503B [15]. Manufacturing purity and peptide sequence verification are identified concerns [15]. The correct BPC-157 sequence is GEPPPGKPADDAGLV [1]. Verification requires HPLC and mass spectrometry analytical methods. WADA's S0 prohibition renders BPC-157 a banned substance for competitive athletes at all times, with no Therapeutic Use Exemption pathway available [15]. USADA has specifically stated that no safe dose has been established in humans. Long-term safety in any species is poorly characterized. The absence of toxicity in short-to-medium animal studies cannot be interpreted as safety in chronic human use contexts. ## References [1] Krivic A, et al. Achilles detachment and BPC 157. Journal of Orthopaedic Research. 2006. DOI: 10.1002/jor.20096. PMID: 16583442. [2] Chang CH, et al. BPC 157 Enhances GHR Expression. Molecules. 2014. DOI: 10.3390/molecules191119066. PMID: 25415472. [4] Cerovecki T, et al. BPC 157 improves ligament healing. Journal of Orthopaedic Research. 2010. DOI: 10.1002/jor.21107. [5] Xue XC, et al. Protective effects of BPC 157 on gastric ulcer. World Journal of Gastroenterology. 2004. DOI: 10.3748/wjg.v10.i7.1032. PMID: 15052688. [6] Klicek R, et al. BPC 157 in the healing of colocutaneous fistulas. Journal of Pharmacological Sciences. 2008. DOI: 10.1254/jphs.fp0072161. PMID: 18818478. [7] Vukusic D, et al. Duodenocolic fistula healing by BPC 157 in rats. Journal of Physiology and Pharmacology. 2024. DOI: 10.26402/jpp.2024.1.09. PMID: 38583442. [8] Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 in trials for IBD. Inflammopharmacology. 2006. DOI: 10.1007/s10787-006-1531-7. PMID: 17186181. [10] Perovic D, et al. BPC 157 can improve healing of spinal cord injury. Journal of Orthopaedic Surgery and Research. 2019. DOI: 10.1186/s13018-019-1242-6. PMID: 31266512. [13] He L, et al. Pharmacokinetics of BPC 157 in rats and dogs. Frontiers in Pharmacology. 2022. DOI: 10.3389/fphar.2022.1026182. PMID: 36588717. [14] Japjec M, et al. BPC 157 for Myotendinous Junctions in Rats. Biomedicines. 2021. DOI: 10.3390/biomedicines9111547. PMID: 34829776. [15] McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157. Current Reviews in Musculoskeletal Medicine. 2025. DOI: 10.1007/s12178-025-09990-7. PMID: 40789979. [17] Concerning BPC-157, a natural pentadecapeptide. Inflammopharmacology. 2025. DOI: 10.1007/s10787-025-01882-z. PMID: 40759852. --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.